| 证券代码：300401 | 证券简称：花园生物 公告编号：2025-011 | | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | 浙江花园生物医药股份有限公司 第七届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏 一、会议召开情况 浙江花园生物医药股份有限公司（以下简称"公司"）第七届董事会第八次会议于 2025年3月21日在公司会议室以现场方式召开，会议通知于2025年3月12日以微信、电子 邮件等方式送达全体董事。会议应到董事9人，实到董事9人。本次会议由董事长邵徐君 先生主持，公司监事、高级管理人员列席了会议。会议的召集和召开符合《公司法》《公 司章程》的有关规定。 二、会议审议情况 会议以记名投票的方式进行表决，经与会董事认真审议，形成如下决议： (一) 审议通过了《关于2024年度董事会工作报告的议案》 公司董事会已就2024年度工作进行了分析总结。公司在任独立董事严建苗、厉国威、 杨启炜向董事会递交了《2024年度独立董事述职报告》，并将在公司2024年年度股东会 上述职。 公司董事会对 ...

浙江花园生物医药股份有限公司 关于 2024 年度利润分配方案的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏 一、 审议程序 浙江花园生物医药股份有限公司（以下简称"公司"）于 2025 年 3 月 21 日召开 第七届董事会独立董事专门会议、第七届董事会第八次会议、第七届监事会第五次会 议，审议通过了《关于 2024 年度利润分配方案的议案》。 1、独立董事专门会议审议情况 | 证券代码：300401 | 证券简称：花园生物 | 公告编号：2025-004 | | --- | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | | 第七届董事会独立董事专门会议审议了该议案，独立董事认为：2024 年度公司 利润分配方案符合法律、法规及《公司章程》等相关规定，符合公司整体发展战略， 有利于公司的持续稳定健康发展，不存在损害公司及全体股东尤其中小股东的利益的 情形。独立董事同意将此议案提交公司董事会审议。 2、董事会审议情况 2025 年 3 月 21 日，公司召开的第七届董事会第八次会议，审议通过了《关于 2024 年度利润分配方案 ...

Financial Performance - The company's revenue for 2024 reached ¥1,243,283,228.76, representing a 13.58% increase compared to ¥1,094,651,559.54 in 2023 [22]. - Net profit attributable to shareholders increased by 60.76% to ¥309,212,798.15 from ¥192,348,873.69 in the previous year [22]. - The net profit after deducting non-recurring gains and losses rose by 74.02% to ¥256,888,423.11, up from ¥147,616,823.26 in 2023 [22]. - The net cash flow from operating activities surged by 191.53% to ¥466,406,332.89, compared to ¥159,984,577.98 in the previous year [22]. - Basic earnings per share increased by 62.86% to ¥0.57 from ¥0.35 in 2023 [22]. - Total assets at the end of 2024 amounted to ¥5,612,645,527.96, a 6.69% increase from ¥5,260,592,068.07 in 2023 [22]. - Net assets attributable to shareholders grew by 11.24% to ¥3,218,400,077.44, compared to ¥2,893,130,267.00 at the end of 2023 [22]. - The weighted average return on equity for 2024 was 10.17%, up from 7.30% in the previous year [22]. Dividend Distribution - The company plans to distribute a cash dividend of 1.14 CNY per 10 shares to all shareholders, based on a total share capital of 543,467,249 shares [6]. - The company will not issue bonus shares or increase capital reserves in the current profit distribution plan [6]. - For the fiscal year 2024, the company will distribute a cash dividend of RMB 1.14 per 10 shares, amounting to RMB 61,955,266.39, with no stock bonus or capital increase [144]. - The company's net profit for 2024 is reported at RMB 309,212,798.15, with available distributable profits of RMB 1,753,020,180.53 [144]. Risk Management - The company emphasizes the importance of understanding risks related to industry cyclicality, drug price declines, and procurement failures in the vitamin sector [5]. - Future development plans and forward-looking statements do not constitute substantial commitments to investors, highlighting the need for cautious decision-making [5]. - The management discussion section outlines potential risks and challenges the company may face in its operations [5]. - The company recognizes risks related to vitamin price fluctuations, which significantly impact revenue due to the high proportion of vitamin product sales [104]. - The company faces project investment risks, as the construction of funded projects may encounter uncertainties in progress, implementation, and effectiveness [104]. - The company is exposed to risks from changes in medical reform policies that could alter market competition and business models [104]. - The company anticipates continued downward pressure on drug prices due to government policies aimed at reducing medical costs, which may negatively affect profitability [104]. Research and Development - The company plans to continue expanding its product lines and enhance R&D efforts in innovative drugs and technologies [22]. - The company emphasizes R&D investment and has a sustainable product development pipeline for new product research and technology innovation [50]. - The company has three R&D centers in Dongyang, Jinhua, and Hangzhou, focusing on natural product biosynthesis, industrialization research, and cutting-edge drug trials [51]. - The company is currently conducting multiple R&D projects aimed at enriching its product line and enhancing market competitiveness [77]. - The company has ongoing projects in various stages, with several products awaiting approval for market launch [77]. Market Expansion and Strategy - The company is actively pursuing market expansion strategies and potential mergers and acquisitions to strengthen its market position [22]. - The company has established a comprehensive vitamin D3 industrial chain, becoming the only global producer with this capability [53]. - The company has outlined a strategy to enhance its product offerings and market expansion efforts in the future [166]. Environmental and Social Responsibility - The report will cover significant environmental and social responsibility issues faced by the company [10]. - The company has established a standardized hazardous waste storage facility and strictly follows electronic tracking for hazardous waste disposal [153]. - The company adheres to various environmental standards for air and water pollutants, ensuring compliance with industry regulations [153]. - The company achieved an A-level performance rating in environmental management from Zhejiang Province in 2024 [158]. - The company emphasizes a green development philosophy, focusing on source reduction, process control, and end treatment of waste [155]. Corporate Governance - The company maintains a complete and independent business system, ensuring no interference from controlling shareholders [121]. - The company has a robust organizational structure with independent operation of its internal governance bodies [121]. - The management team includes experienced professionals, with the current general manager, Ma Huanzheng, having been with the company since 2000 [123]. - The company has a structured decision-making process for determining the remuneration of its board members and executives [128]. - The board of directors held a total of 8 meetings during the reporting period, with all members actively participating [131]. Financial Management - The company has maintained effective internal control over financial reporting as of December 31, 2024, according to the internal control audit report [151]. - The internal control audit report received a standard unqualified opinion, confirming alignment with the self-evaluation report [151]. - The company has implemented a continuous optimization of its internal control management system to enhance risk prevention capabilities [150]. - The company has established measures to ensure compliance with public commitments made by its controlling shareholders and management personnel [166]. Employee Management - The company is committed to improving employee salary levels and welfare, contributing to rural revitalization and common prosperity [161]. - The total number of employees at the end of the reporting period is 1,021, with 211 in the parent company and 810 in major subsidiaries [138]. - The professional composition includes 567 production personnel, 51 sales personnel, 229 technical personnel, 60 financial personnel, and 114 administrative personnel [138]. - The company has established a comprehensive training system to enhance employee skills and align with strategic goals [140]. Subsidiaries and Investments - The company established Zhejiang Garden Biomedicine Engineering Co., Ltd. with a registered capital of RMB 200 million, holding a 90% stake [176]. - The company has not sold any major assets during the reporting period [101]. - The actual amount of related party transactions during the reporting period was CNY 114.82 million, while the approved transaction amount for 2024 is expected to be CNY 160 million [183].

| 证券代码：300401 | 证券简称：花园生物 | 公告编号：2025-003 | | --- | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | | 浙江花园生物医药股份有限公司 关于可转换公司债券 2025 年付息的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 2、债权登记日：2025年3月5日（星期三） 3、付息日：2025年3月6日（星期四） 4、除息日：2025年3月6日（星期四） 5、本次付息期间及票面利率：计息期间为2024年3月6日至2025年3月5日，票面利 率为0.50%。 6、本次付息的债权登记日为2025年3月5日。凡在2025年3月5日（含）前买入并持 有本期债券的投资者享有本次派发的利息，2025年3月5日（含）前卖出本期债券的投资 者不享有本次派发的利息。在付息债权登记日前（包括付息债权登记日）申请转换成公 司股票的可转换公司债券，公司不再向其持有人支付本计息年度及以后计息年度的利 息。 7、下一付息期起息日：2025年3月6日 8、下一年度票面利率：1.0% 浙江花园生物医药股份有限公 ...

Financial Performance - The net profit attributable to shareholders is expected to be between 300 million and 350 million yuan, representing a year-on-year growth of 55.97% to 81.96%[3] - The net profit after deducting non-recurring gains and losses is projected to be between 250 million and 290 million yuan, indicating a year-on-year increase of 69.36% to 96.45%[3] - The overall operating revenue is expected to rise by around 13%, with total gross profit increasing by approximately 10%[5] Segment Performance - Revenue from the vitamin segment increased by approximately 55%, with gross profit rising by about 77%[5] Expenses and Gains - Marketing expenses for pharmaceutical products decreased by about 24% compared to the previous year[5] - The company recognized asset disposal gains of approximately 31 million yuan from the relocation of its Hangzhou subsidiary[5] - Non-recurring gains and losses are estimated to impact net profit by 50 million to 60 million yuan, mainly from subsidiary relocation asset disposal gains and government subsidies[6] Financial Reporting - The company has communicated with the accounting firm regarding the preliminary financial data, with no significant discrepancies reported[4] - The financial data provided is preliminary and will be detailed in the 2024 annual report, urging investors to exercise caution[7] - The performance forecast period is from January 1, 2024, to December 31, 2024[3]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 | 证券代码：300401 | 证券简称：花园生物 公告编号：2025-001 | | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | 浙江花园生物医药股份有限公司 关于 2024 年第四季度可转换公司债券转股情况公告 （三）可转换公司债券转股期限 重要内容提示： 1、"花园转债"（债券代码：123178）转股期限为2023年9月11日至2029年3月5日； 最新的转股价格为人民币13.56元/股。 2、2024年第四季度，共有404张"花园转债"完成转股（票面金额共计人民币 40,400.00元），合计转成2,973股"花园生物"股票（证券代码：300401）。 3、截至2024年第四季度末，"花园转债"剩余债券张数为11,760,281张，剩余票面 总额为人民币1,176,028,100.00元。 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公司自律监 管指引第15号——可转换公司债券》的有关规定，浙江花园生物医药股份有限公司（以 下简称"公司"）现将2024 ...

财联社12月31日电，花园生物公告称，公司拟在澳门设立子公司，主要从事大健康的研发、生产和销 售。 公司名称暂定为花园力维(澳门)生物科技有限公司，注册资本为1,000万澳门元。 经营范围包括化学药、生物制品、中药、保健品、保健食品、化妆品、医疗器械的研发、生产及销售 等。 公司将持股80%，全资子公司浙江花园营养科技有限公司持股20%。 ...

关于浙江花园生物医药股份有限公司 民生证券股份有限公司 2024 年度持续督导培训情况的报告 根据《证券发行上市保荐业务管理办法》《深圳证券交易所上市公司自律监 管指引第 13 号——保荐业务》等有关规定的要求，作为浙江花园生物医药股份 有限公司（以下简称"花园生物"或"公司"）2023 年向不特定对象发行可转换 公司债券持续督导的保荐机构，民生证券股份有限公司（以下简称"保荐机构"） 于 2024 年 12 月 17 日对花园生物实际控制人、控股股东、董事、监事、高级管 理人员及其他相关人员进行了 2024 年度持续督导现场培训，对于未现场参与培 训的人员，持续督导项目组已向花园生物发送了本次培训资料，提请公司转发至 因故未能参加培训的相关人员，以供自学。 一、培训内容 本次培训通过演示培训讲义、解读法规条文等形式进行，重点对上市公司股 东董监高减持最新规则、募集资金使用和管理相关规则、信息披露及规范运作最 新规则等方面进行了阐述分析，并介绍了部分监管案例。 二、培训对象 花园生物接受培训的人员为公司的实际控制人、控股股东、董事、监事、高 级管理人员及其他相关人员。 三、培训效果 保荐机构认为，通过本次培训 ...

民生证券股份有限公司 关于浙江花园生物医药股份有限公司 2024 年度持续督导定期现场检查报告 | 保荐机构名称：民生证券股份有限公司 被保荐公司简称：花园生物 | | | | | --- | --- | --- | --- | | 保荐代表人：谢广化 联系电话：010-85127999 | | | | | 保荐代表人：肖舜华 联系电话：010-85127999 | | | | | 现场检查人员：谢广化、肖舜华 | | | | | 现场检查对应期间：2024 年度 | | | | | 现场检查时间：2024 年 12 月 16 日-2024 年 12 月 18 日 | | | | | 一、现场检查事项 | | 现场检查意见 | | | （一）公司治理 | 是 | 否 | 不适用 | | 现场检查手段：查阅、复制、检查、访谈 | | | | | 1.公司章程和公司治理制度是否完备、合规 | √ | | | | 2.公司章程和三会规则是否得到有效执行 | √ | | | | 3.三会会议记录是否完整，时间、地点、出席人员及会议内容 | √ | | | | 等要件是否齐备，会议资料是否保存完整 | | | | | ...

证券代码：300401 证券简称：花园生物 公告编号：2024-077 债券代码：123178 债券简称：花园转债 浙江花园生物医药股份有限公司 2024年12月20日 经浙江花园生物医药股份有限公司（以下简称"公司"）2023年年度股东大会 审议通过，聘请北京大华国际会计师事务所（特殊普通合伙）为公司2024年度财务 审计机构和内部控制审计机构（公告编号：2024-032）。 公司于近日收到北京大华国际会计师事务所（特殊普通合伙）来函，北京大华 国际会计师事务所（特殊普通合伙）名称已变更为北京德皓国际会计师事务所（特 殊普通合伙）。更名后的事务所各项执业资格、服务团队、单位地址、联系电话等 均无变化，主体资格和法律关系不变。原北京大华国际会计师事务所（特殊普通合 伙）的各项业务、权利和义务由北京德皓国际会计师事务所（特殊普通合伙）继续 承担，原有的业务关系及已签订的合同继续履行，服务承诺保持不变。 因此，本次会计师事务所名称变更，不涉及主体资格变更，不属于更换或重新 聘任会计师事务所的情形。 特此公告。 关于会计师事务所名称变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载 ...